Company intelligence / Profile preview

Bicara Therapeutics

Boston, Massachusetts, United Statesbicara.com ↗

Ownership: Public · BCAX
Employees: ~55
Development stage: Phase 1

Overview

Bicara’s lead asset, ficerafusp alfa, has shown encouraging interim Phase 1/1b data demonstrating durable and clinically meaningful anti-tumor activity in combination with pembrolizumab. The company has initiated a pivotal global Phase 2/3 trial in first-line recurrent/metastatic HNSCC. Additional expansion cohorts are ongoing or planned across multiple solid tumor indications

Therapeutic areas: Oncology
Modalities: Bifunctional antibodies (biologics engineered to combine tumor-targeting and tumor microenvironment modulation)
Industry: Biotech

Drug pipeline

3 assets

ficerafusp alfa

2 more assets in the full pipeline.

Request access →

Partnerships

Pembrolizumab supplied by Merck & Co. for combination trials; no major disclosed pharma partnerships as of May 2025.

Financials

Market cap: $1.6B
Total revenue: $0
Enterprise value: $1.1B

Beyond the preview

Go deeper on Bicara Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bicara Therapeutics.

Explore the full profile